Our study showed significant improvements in eGFR and reductions in creatinine, likely due to the renoprotective effects of SGLT2 inhibitors in patients with CKD and better hydration management, while Pathan et al.'s study found no significant changes, possibly due to stable medication use, healthier baseline renal function, and transient effects of fasting conditions. Here, SLC5A2 is linked to chronic kidney disease.